ASP0739

Phase 1/2Terminated
0 watching 0 views this week Active
41
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer

Conditions

Ovarian Cancer, NSCLC, ESCC, Solid Tumors

Trial Timeline

Dec 23, 2021 → Jun 1, 2023

About ASP0739

ASP0739 is a phase 1/2 stage product being developed by Astellas Pharma for Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04939701. Target conditions include Ovarian Cancer, NSCLC, ESCC.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04939701Phase 1/2Terminated

Competing Products

20 competing products in Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
44
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
33
pemetrexed + topotecanEli LillyPhase 1
33
arzoxifene hydrochlorideEli LillyPhase 2
52
LY4337713Eli LillyPhase 1
33
PrexasertibEli LillyPhase 2
52
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabBioAtlaPhase 2
44
Gemcitabine + Oxaliplatin + BevacizumabEli LillyPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
52
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
52
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
41
Enzalutamide 40 MGAstellas PharmaPhase 2
52
IMAB027Astellas PharmaPhase 1
33
OSI-211 (Liposomal Lurtotecan)Astellas PharmaPhase 2
52
Triptorelin for Injection + Recombinant Human Choriogonadotropin alfa Solution for Injection + Progesterone Soft CapsulesSun PharmaceuticalPhase 3
77
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52